secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0000920148-25-000075
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q2 revenue $3.53B, Adj EPS $4.35; raises full-year guidance
-------------------------------------------------------------------

- Q2 revenue $3.53B (+9.5% YoY); diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94.
- Full-year guidance raised: revenue growth 7.5%-8.6%; adjusted EPS $16.05-$16.50; FCF $1.13-$1.28B.
- Diagnostics Labs revenue $2.75B (+8.9%); Biopharma Lab Services $784.8M (+11.0%).
- Quarterly dividend $0.72/share declared; $200M stock repurchased in Q2.
- Announced acquisitions of select assets from Incyte Diagnostics, BioReference Health, and Community Health Systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000075/0000920148-25-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000075/lh-20250724.htm
  HTML page:      https://secwatch.observer/filing/0000920148-25-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer